FY2027 Earnings Estimate for Novavax Issued By HC Wainwright

Novavax, Inc. (NASDAQ:NVAX) – Research analysts at HC Wainwright issued their FY2027 earnings estimates for Novavax in a research report issued on Thursday, October 23rd. HC Wainwright analyst S. Lee forecasts that the biopharmaceutical company will post earnings of $0.23 per share for the year. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. HC Wainwright also issued estimates for Novavax’s FY2029 earnings at $0.82 EPS.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a report on Saturday. Cantor Fitzgerald assumed coverage on shares of Novavax in a research report on Friday. They set an “overweight” rating and a $18.00 target price for the company. Finally, Bank of America restated an “underperform” rating and set a $7.00 target price (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $11.33.

Novavax Price Performance

Shares of NVAX opened at $8.52 on Friday. The firm has a market capitalization of $1.38 billion, a PE ratio of 3.74, a price-to-earnings-growth ratio of 0.12 and a beta of 2.74. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. Novavax has a 1-year low of $5.01 and a 1-year high of $11.55. The company’s fifty day moving average price is $8.40 and its 200-day moving average price is $7.44.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.69. The firm had revenue of $239.24 million for the quarter, compared to analyst estimates of $149.19 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The business’s quarterly revenue was down 42.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.99 earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bayforest Capital Ltd acquired a new position in shares of Novavax in the first quarter worth about $404,000. Kingstone Capital Partners Texas LLC acquired a new position in shares of Novavax in the second quarter worth about $1,016,000. Park West Asset Management LLC acquired a new position in shares of Novavax in the first quarter worth about $16,210,000. Shah Capital Management raised its position in shares of Novavax by 3.4% in the second quarter. Shah Capital Management now owns 11,511,780 shares of the biopharmaceutical company’s stock worth $72,524,000 after acquiring an additional 379,934 shares during the period. Finally, Entropy Technologies LP acquired a new position in shares of Novavax in the first quarter worth about $191,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.